Cover of Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System

Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System

Workshop Summary

.

Washington (DC): National Academies Press (US); .
ISBN-13: 978-0-309-21221-2ISBN-10: 0-309-21221-9
Copyright © 2011, National Academy of Sciences.
Read

Excerpt

Although glutamate has a staggering array of functions, none of the top-selling CNS drugs is indicated directly for rectifying dysfunction at the glutamate synapse. Currently, three prescription drugs approved by the Food and Drug Administration (FDA)—memantine, ketamine, and D-cycloserine—have implications for diseases of glutamate or glutamate-related pathology. Many workshop participants agreed that the lack of glutamate biomarkers is the largest obstacle to increasing glutamate-specific drug development. In spite of this problem, scientific progress is close to a tipping point that will yield novel glutamate biomarkers as long as concerted efforts are undertaken by academic, government, and industry researchers, as well as by health policy makers. The stakes, in their view, are too great to disregard.